Trokendi XR Helps Partial Onset and Seizures Associated with Lennox-Gastaut Syndrome
The Food & Drug Administration has issued final approval for Trokendi XR, an extended-release oral formulation of topiramate for treatment of epilepsy. The medicine is expected to be available in pharmacies within the next few weeks in 25, 50, 100, and 200 mg extended-release capsules.
According to manufacturer Supernus, Trokendi XR is an antiepilepsy drug to assist patients aged 10 and up with partial onset or primary generalized tonic-clonic seizures. In addition, it is approved for adjunctive therapy in patients six years of age and older with partial onset or primary generalized tonic-clonic seizures, and adjunctive therapy in patients six years of age and older with seizures associated with Lennox-Gastaut syndrome.
“It is imperative that we continue to explore new ways to help those living with epilepsy and we are very grateful for the work of Supernus in receiving FDA approval for Trokendi XR,” said Phil Gattone, president and CEO of the Epilepsy Foundation. “With less than 40 antiepilepsy medications currently available to help – and much fewer for severe syndromes like Lennox-Gastaut – it is imperative that pharmaceutical companies continue to innovate and improve upon treatments. New treatments must receive government approvals as fast as possible.”
For more information on Trokendi XR, visit Supernus.com.